Treatment of sepsis: What changed during the last decades?

Acta Anaesthesiologica Scandinavica, Supplement

Volumn 41, Issue 111, 1997, Pages 174-176

  Reinhart, K ^a   Karzai, W ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BIOLOGICAL MARKER; ENDOTOXIN; IMMUNOLOGICAL ADJUVANT; ANTIBIOTIC AGENT;

ARTICLE; CIRCULATION; DRUG ANTAGONISM; FLUID THERAPY; HEART OUTPUT; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE; MICROBIOLOGY; OXYGEN CONSUMPTION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR RESISTANCE; ANTIBIOTIC THERAPY; BLOOD FLOW; CONFERENCE PAPER; CRITICAL ILLNESS; INFLAMMATION; MORTALITY; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BIOLOGICAL MARKERS; BLOOD CIRCULATION; CARDIAC OUTPUT; ENDOTOXINS; FLUID THERAPY; HUMANS; IMMUNOTHERAPY; INTENSIVE CARE; OXYGEN CONSUMPTION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR RESISTANCE;

EID: 0031305997     PISSN: 05152720     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Increases in national hospital discharge survey rates for septicemia-United States, 1979-1987. MMWR 1990: 39: 31-34.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidlines for the use of innovative therapies in sepsis. Crit Care Med 1992: 20: 864-874.
3. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994: 154: 26-34.
4. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993: 341: 515-518.
5. Dofferhoff AS, Esselink MT, de Vries Hospers HG et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 1993: 31: 373-384.
6. Cunnion RE, Shaer GL, Parker MM et al. The coronary circulation in human septic shock. Circulation 1986: 73: 637-644.
7. Kumar A, Parrillo JE. Clinical manifestations of cardiovascular dysfunction in sepsis. In: Schlag G, Redl H, eds. Patho-physiology of Shock, Sepsis, and Organ Failure. Berlin: Springer-Verlag, 1994: 859-881.
8. Abel FL, Bond RF, Augustine SD. Hemodynamic responses to changes in carotid sinus pressure after endotoxin and ibuprofen. Circ Shock 1993: 39: 7-14.
9. Shoemaker WC, Appel P, Kram HB et al. Hemodynamic and oxygen transport monitoring to titrate therapy in human septic shock. New Horizons 1993: 1: 145-159.
10. Vincent J-L, Roman A, Kahn RJ. Dobutamine administration in septic shock: Addition to a standard protocol. Crit Care Med 1990: 18: 689-693.
11. Tuchschmidt J, Fried J, Swinney R et al. Early hemodynamic correlations of survival in patients with septic shock. Crit Care Med 1989: 17: 719-723.
12. Hayes MA, Timmins AC, Zau EHS et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engt J Med 1994: 330: 1717-1722.
13. Gattinoni L, Brazzi L, Pelosi P et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995: 333: 1025-1032.
14. Fiddian-Green RG. Gut mucosal ischemia during cardiac surgery. Sem Thorac Cardiovasc Surg 1990: 2: 389-399.
15. Meier-Hellmann A, Reinhart K. Influence of catecholamines on regional perfusion and tissue oxygenation in septic shock patients. In: Reinhart K, Eyrich K, Sprung C, eds. Sepsis: Current perspectives in pathophysiology and therapy. Berlin: Springer-Verlag, 1994: 274-291.
16. Meier-Hellmann A, Bredle DL, Specht M et al. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997: 23: 31-37.
17. Meier-Hellmann A, Reinhart K, Bredle DL et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997: 25: 399-404.
18. Natanson C, Eichenholz PW, Danner RL et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989: 169: 823-832.
19. Ziegler EJ, McCutchen A, Fierer J et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982: 307: 1225-1230.
20. Ziegler EJ, Fisher CJJ, Sprung CL et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled study. N Engl J Med 1991: 324: 429-436.
21. Greenman RL, Schein RM, Martin MA et al. A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991: 266: 1097-1102.
22. McCloskey RV, Straube RC, Sanders C et al. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Int Med 1994: 121: 1-5.
23. Natanson C, Hoffman WD, Suffredini AF et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994: 120: 771-783.
24. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996: 77: 110-117.
25. Lehrer RI, Ganz T, Selsted ME et al. Neutrophils and host defense. Ann Int Med 1988: 109: 127-142.
26. Parrillo JE. Septic shock in humans: Clinical evaluation, pathogenesis, and therapeutic approach. In: Shoemaker WC Ayres S, Grenvik A, Holbrook PR, Thompson WL, eds. Textbook of Critical Care. Philadelphia: W. B. Saunders, 1989 1006-1024.
27. Cronin L, Cook DJ, Carlet J et al. Corticoid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995: 23: 1430-1439.
28. Reinhart K, Wiegend-L-hnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with scepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care, Med 1996: 24: 733-742.
29. Fisher CJ, Jr., Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996: 334: 1697-1702.
30. Fisher CJ, Jr., Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994: 271: 1836-1843.
31. Correspondence Prof. Dr. med. K Reinhart Klinik für Anästhesiologie und Intensivtherapy Klinkum der Friedrich-Schiller-Universität Jena Bachstr. 18 07740 Jena, Germany